Using ELISA immunoassays, our study showed that the mean protein MMP9 level was significantly elevated in the serum of GBM patients compared with the serum of grade III patients (Fig. 6A), suggesting it may aid discrimination between these two grades, although the difference with the control group was not significant. This evidence concerns the gene MMP9 and glioblastoma.